Introduction
Multiple myelomatosis is a fatal disease associated with the generalized proliferation of abnormal plasma cells in the bone marrow; it may be preceded by a localized tumour (plasmacytoma) . The Because of the small numbers, the patients presenting with plasmacytoma have not been analysed further.
The age of the patient at the time of diagnosis of multiple myelomatosis influenced the survival time (Table 3) , and women, in spite of being slightly older, had a significantly better prognosis than men (Table 4 ). The mean survival time of the eighty-nine men who had died was 5 9 months compared vith 13-2 months for the fifty women: this latter mean survival time for women fell to 8-7 months when three women with an unusually long survival time were excluded. Data on the survival time related to the presenting symptoms of 138 patients are presented in Table 5 . There was no significant difference in the length of survival between patients who presented with orthopaedic symptoms, with haematological features, or initial level over 60 mg/100 ml survived more thai 3 months compared with sixty-five of the eightyeight (74%4) with an initial urea of under 60 mg/100 ml. The sex difference in prognosis is not explained by a greater number of men with a raised urea leveltwenty-five of the seventy-eight men (32%4) had a urea level of 60 mg/100 ml and above, compared to fifteen of the fifty women (30%°).
The serum calcium level was raised (5 5 mEq/l and over) in seventeen of the seventy-eight patients in whom it was measured at the time of diagnosis. There was no clear-cut trend in survival time of these patients.
The haemoglobin level at the time of diagnosis was normal (over 13 g/100 ml) in only fourteen of the 138 patients with multiple myelomatosis (10-4%y)
The initial haemoglobin level, however, bore little relation to the length of survival except that patients with a very low haemoglobin level had a higher immediate mortality: many of these patients were severely uraemic and the poor survival was related to the urea level rather than the haemoglobin level per se. Thus, of the twenty patients with a haemoglobin level of 7 0 g/100 ml or below, the twelve with a urea of 50 mg/100 ml and over had a mean survival time of 3-8 months compared with 8-0 months for the eight patients with a urea level of under 50 mg/100 ml.
group.bmj.com on July 10, 2017 -Published by http://pmj.bmj.com/ Downloaded from Thirty-one of the 147 patients with multiple myelomatosis whose blood film was examined had an abnormal blood picture at the time of presentation-either plasma cells were present or there was a leuco-erythroblastic blood picture. The survival time in these patients did not differ significantly from that of the remaining patients (x2=2-33, d.f.=2, P> 0 1).
The patients with multiple myelomatosis received a wide range of therapy. For convenience of presentation this has been divided into four groups radiotherapy alone, radiotherapy with chemotherapy, chemotherapy alone, and either adrenocorticosteroid alone or no specific therapy. The dosage of radiotherapy varied considerably within the palliative dose range. Chemotherapeutic drugs used included melphalan and cyclophosphamide and, occasionally, uracil mustard. Some earlier patients received urethane. Some of the patients receiving radiotherapy or chemotherapy also received steroid therapy. It should be emphasized that many of the patients who did not get specific therapy were admitted moribund or severely uraemic and died before appropriate therapy could be commenced. Table 6 shows that combined radiotherapy with chemotherapy was associated with the longest survival time. 
Discussion
This survey points again to the poor overall survival in multiple myelomatosis. Our survival times are shorter than in most previously reported series (Martin, 1961; Innes & Newall, 1961; Alexanian et al., 1969; Hobbs, 1969) ; it is likely that this difference is due, at least in part, to the strict diagnostic criteria used in this survey and to the inclusion of all patients admitted to hospital with multiple myelomatosis. The survival time did not differ markedly from the unselected series reported by Feinleib & McMahon (1960) .
The patients with plasmacytoma survived, on average, considerably longer than the patients with multiple myelomatosis. Indeed, all those with extraosseous tumours survived many years, some in spite of the development of several distant recurrent tumours. Prolonged survival in extra-osseous plasmacytoma has been noted previously (Hellwig, 1943) . The better prognosis in plasmacytoma may merely represent diagnosis at an earlier stage in the disease; Bergsagel and his associates (1967) have stressed that patients with plasmacytoma almost always progress to multiple myelomatosis.
Both the age and the sex of the patients were found to influence prognosis significantly. There is general agreement that survival times become less as age at diagnosis increases (Feinleib & McMahon, 1960; Galton & Peto, 1968) . The longer survival times of female patients with multiple myelomatosis has been noted by Videbaek & Johansen (1956 ), Feinleib & McMahon (1960 and Waldenstrom (1968) , but women were reported to have a poorer prognosis by Galton & Peto (1968) .
There is general agreement that a raised blood urea at the time of presentation of multiple myelomatosis is associated with a poor prognosis (Bergsagel et a!., 1967; Broad et al., 1968; Galton & Peto, 1968 ; Report of the Medical Research Council Trial of Melphalan and Cyclophosphamide Therapy, 1971 ). In the present series an initial blood urea of 60 mg/100 ml was found to be a critical level as an indicator of probable short survival.
In contrast to the experience of Innes & Newall (1961 ), Broad et al. (1968 and Galton & Peto (1968) , we have no evidence that a low haemoglobin per se, in the presence of a normal blood urea level, affects prognosis adversely; this was also the conclusion of Rivers & Patno (1969) but only when they considered patients who survived more than 6 weeks. Similarly, the, presence of peripheral blood film abnormalities, due to marrow involvement by plasma cells, did not significantly affect prognosis.
This survey was not planned to assess the effect of therapy on prognosis in myelomatosis and a wide variety of therapeutic regimens was used. Patients who received both chemotherapy and radiotherapy during the course of their illness had the longest survival, but this may merely reflect the time available to employ such therapy. Indeed, the high death-rate in the first 3 months after presentation in an unselected series of patients indicates the artificiality of survival times calculated from series where these patients are excluded as in trials of therapeutic agents (Alexanian et aL., 1969; Hobbs, 1969) .
